SNN vs. ENOV, ALGN, STE, ZBH, RDY, SOLV, UTHR, CRL, DVA, and UHS
Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include Enovis (ENOV), Align Technology (ALGN), STERIS (STE), Zimmer Biomet (ZBH), Dr. Reddy's Laboratories (RDY), Solventum (SOLV), United Therapeutics (UTHR), Charles River Laboratories International (CRL), DaVita (DVA), and Universal Health Services (UHS). These companies are all part of the "medical" sector.
Smith & Nephew (NYSE:SNN) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.
Smith & Nephew has higher revenue and earnings than Enovis.
Enovis has a consensus target price of $75.43, suggesting a potential upside of 43.92%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Smith & Nephew.
25.6% of Smith & Nephew shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by company insiders. Comparatively, 2.4% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Smith & Nephew has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.
In the previous week, Smith & Nephew and Smith & Nephew both had 4 articles in the media. Smith & Nephew's average media sentiment score of 1.04 beat Enovis' score of 0.44 indicating that Smith & Nephew is being referred to more favorably in the media.
Smith & Nephew received 420 more outperform votes than Enovis when rated by MarketBeat users. However, 60.00% of users gave Enovis an outperform vote while only 54.35% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a net margin of 0.00% compared to Enovis' net margin of -4.51%. Enovis' return on equity of 3.98% beat Smith & Nephew's return on equity.
Summary
Enovis beats Smith & Nephew on 9 of the 15 factors compared between the two stocks.
Get Smith & Nephew News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Smith & Nephew Competitors List
Related Companies and Tools
